01 Adaptive chemo-radiotherapy for head and neck cancer based on multiparametric MRI: Interim results of a prospective randomized trial. Avraham Eisbruch, University of Michigan, Ann Arbor, United States.

02 Interpretation of real-time in-vitro head and neck cancer stem cell reporters in response to chemotherapy. Alexander Pearson, University of Michigan, Ann Arbor, MI, United States.

03 Imaging characteristics of head and neck tumors according to human papillomavirus (HPV) status in Bogotá, Colombia. Paula Rodríguez-Urrego, Fundación Santa Fe de Bogotá, Bogotá, Colombia.

04 Caspase-8 is a novel candidate driver gene in head and neck squamous cell carcinoma. Curtis Pickering, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

05 Untangling the gene-epigenome networks: Timing of epigenetic regulation of gene expression in acquired cetuximab resistance gene programs. Elana Fertig, Johns Hopkins University, Baltimore, MD, United States.

06 Comparing mutational profiles between cell-free circulating tumor DNA and tumor DNA in laryngeal carcinoma patients. Adam Greer, Feist Weiller Cancer Center, Shreveport, Louisiana, United States.

07 An oncogenic transcriptional network anchored by ETS1, p63 and subtype specific drivers of HNSCC revealed by epigenomic and genomic interrogation. Christian Gluck, SUNY Buffalo, Buffalo, NY, United States.

08 Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas. Chao Lu, The Rockefeller University, New York, NY, United States.

09 Epigenetic characterization of a subset of head and neck squamous cell carcinoma (HNSCC) unassociated to smoking and alcohol abuse. Sabrina Daniela Silva Wurzba, McGill, Montreal, Canada.

10 Focal adhesion signalling links cell susceptibility to anoikis via pro-inflammatory TRAF2 in head and neck cancer. Sabrina Daniela Silva, McGill, Montreal, Canada.

11 APOBEC is a major source of mutations in head and neck squamous cell carcinoma. Daniel Faden, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.

12 Single cell RNA-seq reveals malignant and stromal programs associated with invasion and metastasis in head and neck cancer. Sidharth Puram, Massachusetts Eye and Ear Infirmary, Boston, MA, United States.
13 Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients. Ashleigh Porter, UC San Diego, Moores Cancer Center, San Diego, California, United States.

14 Elucidation of Genetic Susceptibility Genes Using Next-Generation Sequencing (NGS) Approach in Nasopharyngeal Carcinoma. Maria Lung, University of Hong Kong, Hong Kong, Hong Kong.
15 Utility of chemoradioselection for the optimization of treatment intensity in advanced hypopharyngeal and laryngeal carcinoma. Muneyuki Masuda, National Kyushu Cancer Center, Fukuoka, Fukuoka, Japan.

16 Targeting Metabolic Dysregulation for the Treatment of Radiation Fibrosis. Xiao Zhao, Department of Otolaryngology, University of Toronto, Toronto, Ontario, Canada.

17 Patterns of neck nodal metastases and recurrence in human papilloma virus-associated oropharyngeal squamous cell carcinoma after neck dissection. Madeleine Strohl, University of California San Francisco, San Francisco, CA, United States.


19 Establishment of an Upstream Head and Neck Precision Oncology Tumor Board. Andrew Birkeland, University of Michigan, Ann Arbor, United States.

20 Individualized Outcome Prognostication for Patients with Larynx Cancer. Connor Hoban, University of Michigan, Ann Arbor, MI, United States.

21 Grading Dysphagia as a Toxicity of Head and Neck Cancer: Differences in Severity Classification based on MBS DIGEST and Clinical CTCAE Grades. Ryan Goepfert, MD Anderson Cancer Center, Houston, Texas, United States.

22 Radiation Induce And De-Novo Squamous Cell Carcinoma Of The Temporal Bone - A Comparison. Raymond Tsang, University of Hong Kong, Hong Kong, Hong Kong.

23 A Flexible Next Generation Robotic System For Transoral Robotic Nasopharyngectomy – A Comparative Preclinical Study. Raymond Tsang, University of Hong Kong, Hong Kong, Hong Kong.

24 Comparison of full-thickness versus split-thickness skin graft reconstruction of scalp defects. Xue Zhao, University of Michigan, Ann Arbor, Michigan, United States.

25 Optimizing Patient Selection for Total Laryngectomy versus Larynx-Preservation Chemoradiotherapy for Locally Advanced Laryngeal Squamous Cell Carcinoma: An Analysis of the National Cancer Data Base. Minh Tam Truong, Boston Medical Center, Boston University School of Medicine, Boston, MA, United States.

26 Exosomal microRNA as salivary biomarkers of head and neck squamous cell carcinoma. Scott Langevin, University of Cincinnati, Cincinnati, OH, United States.

27 Ablative Radiotherapy Sensitizes tumors to PD-L1 checkpoint blockade in Squamous Cell Carcinoma of the Head and Neck. Sana Karam, University of Colorado Denver - Anschutz Medical Campus, Aurora, Colorado, United States.

28 Identifying mechanisms of PD-L1 regulation in HNSCC. Jacqueline Mann, University of Michigan, Ann Arbor, Michigan, United States.
29 Mechanistic link between Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA) activity and PDL1 expression in head and neck squamous cell carcinoma (HNSCC). Nicole Michmerhuizen, University of Michigan, Ann Arbor, United States.

30 Small molecule profiling uncovers the landscape of combinatorial PI3K inhibitor responses in HNSCC. Nicole Michmerhuizen, University of Michigan, Ann Arbor, MI, United States.

31 The INSPIRE trial: A randomized trial of neoadjuvant and adjuvant therapy with the IRX-2 regimen in patients with newly diagnosed stage II, III, or IVa squamous cell carcinoma of the oral cavity. Gregory Wolf, University of Michigan, Ann Arbor, MI, United States.

32 The effect of low dose fractionated versus high dose hypofractionated radiotherapy on antitumor immunity. Megan Morisada, National Institutes of Health, Bethesda, MD, United States.

33 CEACAM1 Blockade Increases NK Cell Cytotoxicity in Head and Neck Squamous Cell Carcinoma. Kenric Tam, Stanford School of Medicine, Stanford, CA, United States.

34 Wee1 inhibition sensitizes tumor cells with variable antigenicity to T cell mediated lysis. Ellen Moore, National Institutes of Health, Bethesda, MD, United States.

35 Chemo-Radiotherapy Induces Tolerogenic STAT3 Signaling in Circulating Myeloid-Derived Suppressor Cells in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC). Haejung Won, City of Hope, Duarte, CA, United States.

36 Changes in cellular and molecular immune markers in the peripheral blood of patients undergoing chemotherapy and radiation for squamous cell carcinoma of head and neck: A prospective pilot study. Sagus Sampath, City of Hope National Medical Center, Duarte, California, United States.

37 Anti-OX40 (MEDI6469) prior to definitive surgical resection in patients with head and neck squamous cell carcinoma. R. Bryan Bell, Providence Cancer Center, Portland, OR, United States.

38 Development of a DC-targeted microvesicle vaccine to intercept the progression of oral preneoplasia to cancer. R. Bell, Earle A. Chiles Research Institute, Providence Cancer Center, and the Head and Neck Institute, Portland, OR, United States.

39 Natural Killer cells from primary human head and neck squamous cell carcinomas upregulate inhibitory molecules NKG2A and PD-1. Michael Korrer, Vanderbilt University, Nashville, Tennessee, United States.

40 Immune evasion mechanisms of Smad4 mutant squamous cell carcinomas. Xiao-Jing Wang, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

41 Proteomic stratification of HPV(+) oropharyngeal squamous cell carcinoma identifies targets in insulin receptor signaling within nonresponders. Allen Ho, Cedars-Sinai Medical Center, Los Angeles, CA, United States.

42 Identification of gene expression patterns distinguishing responders and non-responders to induction chemotherapy in sinonasal undifferentiated carcinoma. Yoko Takahashi, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
43 DeSigN identifies CDK4/6 inhibitors for the treatment of head and neck cancer. Sok Ching Cheong, Cancer Research Malaysia, Subang Jaya, Malaysia.

44 Synergistic antitumor activity of olaparib combined with AZD1775 in head and neck squamous cell carcinoma. Hideaki Takahashi, University of Texas, MD Anderson Cancer Center, Houston, Texas, United States.


46 Validation of potential predictive DNA methylation biomarkers for Head and Neck Squamous Cell Carcinoma anatomic subsite. Bianca Rivera, University of Puerto Rico, Rio Piedras Campus, San Juan, PR, United States.


48 Targeting IL-1 signaling to improve tumor response to erlotinib in HNSCC. Andrean Simons, The University of Iowa, Iowa City, IA, United States.

49 Simultaneous Quantification of HPV Oncogene (E6, E7 mRNA) and PD-L1 Protein Expression in Oral Cancer Samples Using Flow Cytometry. Rian Morgan, IncellDx, Menlo Park, California, United States.

50 Plasma concentrations of the DEK oncogene correlate with pathological variables in a case-control study of patients with HNSCC. Lisa Privette Vinnedge, Cincinnati Children's Hospital, Cincinnati, OH, United States.

51 Potential and challenges in co-targeting mTORC and EGFR signaling as a therapeutic strategy in HNSCC. Randall Kimple, University of Wisconsin Madison, Madison, WI, United States.


53 CORO1B amplification and overexpression increases lethality and drives tumor invasiveness in 11q13 amplified HNSCC. Jessica Allen, West Virginia University, Morgantown, WV, United States.

54 Genome-wide CRISPR screen identifies potential therapeutic combination of EGFR and FGFR inhibitors in oral cancer. Megan Ludwig, University of Michigan, Ann Arbor, Michigan, United States.

55 SET protein as a therapeutic target in Head and Neck Squamous Cell Carcinoma. Renata Goto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.

56 SMAD4-deficient HNSCCs are selectively sensitive to combined radiation and PARP inhibition. Ariel Hernandez, University of Colorado, Anschutz Medical Campus, Aurora, CO, United States.
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>57</td>
<td>Detection of cell-free circulating tumor DNA in plasma as a biomarker for treatment-response, prognosis, and recurrence in head and neck squamous cell carcinoma</td>
<td>Stefanie Saunders, Boston University Medical Center, Boston, MA, United States.</td>
<td></td>
</tr>
<tr>
<td>59</td>
<td>Novel mechanisms-guided treatments for betel-nuts related head and neck squamous cell carcinoma in Taiwan.</td>
<td>Jo-Pai Chen, National Taiwan University Hospital, Yun-Lin Branch, Yun-Lin, Taiwan, Taiwan.</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>Characterization of papillary thyroid carcinoma primary cell culture derived cancer stem like cells.</td>
<td>Steve Lee, Loma Linda University, Loma Linda, CA, United States.</td>
<td></td>
</tr>
<tr>
<td>61</td>
<td>Overcoming acquired resistance to PI3K inhibitors in head and neck squamous cell carcinoma with combination treatment.</td>
<td>Aviram Mizrachi, Rabin Medical Center, Petah Tikva, Israel.</td>
<td></td>
</tr>
<tr>
<td>62</td>
<td>Loss of PERP p53/p63 Target Gene May Indicate Tumorigenesis at the Margin and Local Recurrence.</td>
<td>Amanda Simmons, Stanford University, Stanford, CA, United States.</td>
<td></td>
</tr>
<tr>
<td>63</td>
<td>Mutation Profiling of Olfactory Neuroblastoma, Establishment of Novel Olfactory Neuroblastoma Cell Line Models and Results from Drug Screening.</td>
<td>Matt Lechner, Cancer Institute, University College London, London, United Kingdom.</td>
<td></td>
</tr>
<tr>
<td>64</td>
<td>ABNORMAL SPLICING EVENTS IN ADENOID CYSTIC CARCINOMA.</td>
<td>Patrick Ha, University of California Department of Otolaryngology, San Francisco, CA, United States.</td>
<td></td>
</tr>
<tr>
<td>65</td>
<td>Genomic and functional correlates from a phase II clinical trial of trametinib in surgically resectable oral cavity squamous cell carcinoma.</td>
<td>Paul Zolkind, Washington University School of Medicine, Saint Louis, MO, United States.</td>
<td></td>
</tr>
<tr>
<td>66</td>
<td>c-Fos: A new player in promotion of cancer stem-like cell properties in head and neck squamous cell carcinoma.</td>
<td>Ratna Ray, Saint Louis University, St. Louis, MO, United States.</td>
<td></td>
</tr>
<tr>
<td>67</td>
<td>HER3 crosstalk with HPV16-E6E7 is a feedback resistance mechanism to PI3K-targeted therapies in head and neck cancer.</td>
<td>Toni Brand, University of California San Francisco, San Francisco, CA, United States.</td>
<td></td>
</tr>
<tr>
<td>68</td>
<td>Functional interactions of HPV and PARP-1 in head and neck cancer.</td>
<td>Cyril Gary, Yale University School of Medicine, Department of Surgery, Division of Otolaryngology, New Haven, CT, United States.</td>
<td></td>
</tr>
<tr>
<td>69</td>
<td>Proton versus photon irradiation induced cell death in head and neck cancer cells with different human papillomavirus status.</td>
<td>Li Wang, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States.</td>
<td></td>
</tr>
<tr>
<td>70</td>
<td>PARP1 as a potential therapeutic target in Merkel cell carcinoma.</td>
<td>Renata Ferrarotto, University of Texas MD Anderson Cancer Center, Houston, Texas, United States.</td>
<td></td>
</tr>
</tbody>
</table>
71 Role of Autophagy in CYT997 Treatment for Human Head and Neck Squamous Carcinoma. Yong Teng, Augusta university, Augusta, United States.

72 Characterizing <i>NOTCH1</i> loss in head and neck squamous cell carcinoma. Samantha Devenport, University of Michigan, Ann Arbor, MI, United States.

73 Gain-of-Function Mutant p53 Promotes the Oncogenic Potential of Head and Neck Squamous Cell Carcinoma Cell By Targeting Forkhead Transcription Factors FOXO3a and FOXM1. Noriaki Tanaka, The University of Texas MD Anderson Cancer Center, Houston, United States.

74

75 Senescent tumor cells lead the collective invasion in thyroid cancer. Tae Jun Park, Ajou university, Suwon, Republic Of Korea.

76 Randomized phase II study of postoperative RT vs CRT in resected, HPV-negative SCCHN with disruptive TP53 mutations (ECOG 3132). Robert Ferris, University of Pittsburgh, Pittsburgh, PA, United States.